There are several ongoing studies on future therapies for the prevention of venous thromboembolism (VTE).  The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin for the prevention of VTE in acute medically ill patients.  MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for VTE, which aims to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge.
Pulmonary embolism future or investigational therapies
Right heart failure future or investigational therapies
Cardiomegaly future or investigational therapies
Respiratory failure future or investigational therapies
Pulmonary embolism treatment approach
Pulmonary nodule future or investigational therapies
Hemothorax future or investigational therapies
Pulmonary embolism medical therapy